Aclarion Secures AI Patent to Revolutionize Chronic Back Pain Diagnosis

Aclarion, Inc., a commercial-stage healthcare technology company trading on Nasdaq as ACON and ACONW, has secured a significant U.S. Patent (#12,601,803) that strengthens its position in the chronic low back pain market. The patent, titled "System for Machine Learning-Based Model Training and Prediction for Evaluation of Pain," specifically protects the company's machine learning platform for analyzing magnetic resonance spectroscopy (MRS) data. This intellectual property advancement covers Aclarion's use of artificial intelligence in future iterations of its flagship cloud-based platform, Nociscan, which helps physicians distinguish between painful and non-painful spinal discs by converting complex MRS spectral data into clinically actionable insights.

The newly issued patent represents a strategic milestone for Aclarion, expanding its intellectual property portfolio to 64 issued and pending patents worldwide and creating what the company describes as a "long-term competitive moat." According to CEO Brent Ness, the patent strengthens the foundation of their platform by protecting how they leverage AI to transform complex spectroscopy data into meaningful information that physicians can integrate into everyday practice. The technology enables automated biomarker identification, accelerated report generation, and reduced manual quality reviews—capabilities that will help the company scale efficiently while enhancing already strong gross margins. Importantly, the patent also covers AI-based automated data quality controls that detect and exclude low-quality acquisition signals, ensuring consistent, reproducible outputs across different imaging systems and clinical sites.

This development matters because chronic low back pain affects approximately 266 million people worldwide, representing a significant global healthcare challenge. Aclarion's technology addresses this underserved market with evidence showing up to a 97% surgical success rate when all Nociscan-positive discs are treated alongside other diagnostic tools. The patent protection enables Aclarion to build what they call a "differentiated, software-driven platform" that could redefine how spine conditions are assessed. For those interested in learning more about the company's developments, they can visit the Latest News section on Aclarion's website or check the company's newsroom for updates relating to $ACON. The patent itself can be reviewed through the provided link to the USPTO database, offering transparency about the protected technology that could transform pain assessment methodologies.